Pfizer biosimilar to Epogen and Procrit approved by FDA
Pfizer announced the United States Food and Drug Administration approved RETACRIT, a biosimilar to Epogen and Procrit, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent to be approved in the U.S., the company noted. "RETACRIT is expected to be available in the U.S. at a significant discount to the current wholesaler acquisition cost of Epogen and Procrit. WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations. Pfizer has entered into an agreement with Vifor Pharma Inc. for the commercialization of RETACRIT in certain channels. RETACRIT is Pfizer's third approved biosimilar in the U.S. Pfizer's biosimilars pipeline consists of 11 distinct biosimilar molecules with six assets in mid-to-late stage clinical development," the company said.